Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...
GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...
Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback